Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 5Stomach Neoplasms 3Esophageal Neoplasms 3Triple Negative Breast Neoplasms 2Neoplasms 2Liver Neoplasms 2Carcinoma, Hepatocellular 2Squamous Cell Carcinoma of Head and Neck 1Solitary Fibrous Tumors 1Sarcoma, Synovial 1Sarcoma, Ewing 1Sarcoma, Clear Cell 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Salivary Gland Neoplasms 1Osteosarcoma 1Neoplasm Metastasis 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Leiomyosarcoma 1Inflammatory Breast Neoplasms 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Hemangioendothelioma, Epithelioid 1Hemangioendothelioma 1Head and Neck Neoplasms 1HER2-negative Early Breast Cancer 1Esthesioneuroblastoma, Olfactory 1Chondrosarcoma, Extraskeletal Myxoid 1Chondrosarcoma 1

Interventions

Epirubicin 1Docetaxel 1Cyclophosphamide 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × HER2-negative Early Breast Cancer × Epirubicin × Clear all
NCT04836156 2022-04-06

Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for Human Epidermal Growth Factor Receptor 2 (HER2) Negative Early Breast Cancer Patients

Peking University People's Hospital

Phase 1/2 Recruiting
46 enrolled
Breast

HER2-negative Early Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡